Crestor Side Effects Double Those of Other Statin Drugs
Study Shows Adverse Events Even at Lowest Crestor Dose
A new analysis of post-marketing safety reports suggests that patients using Crestor (rosuvastatin) are more likely to develop serious side effects than patients taking Lipitor (atorvastatin), Zocor (simvastatin), or Pravachol (pravastatin).
According to a May 2005 study done at Tufts University, patients taking Crestor are eight times more likely to develop rhabdomyolysis, nephropathy, renal failure or proteinuria than patients taking Pravachol, and 6.5 times more likely to develop those complications than patients taking Lipitor. The study, published in Circulation, an American Heart Association journal, reported that the adverse event risk was 2.2 fold higher for Crestor versus Zocor.
The study was conducted by Dr. Richard H. Karas, Director for the Center for Preventative Cardiology at Tufts University and was an analysis of reports of adverse events experienced by people taking the statin drugs Crestor, Pravachol, or Lipitor. The data was broken down several ways but overall, Crestor was associated with many more adverse event reports than Pravachol or Lipitor, possibly because Crestor is a super-stain and more potent than other statins, even at its lowest dosage.
US consumer group Public Citizen had previously petitioned the FDA to remove Crestor from the market after reports of adverse side effects, but the petition was denied. Public Citizen cited decisions by major U.S. health insurers and by the Swedish government not to reimburse for the drug in support of its FDA petition to remove Crestor.
In addition to the potential for the usual statin drug side effects such as rhabdomyolysis, proteinuria, and nephropathy, Crestor is associated with kidney toxicity, unique among all of the statin drugs.
Read further commentary at: Crestor-Rhabdomyolysis Link: New Study May Support Allegations by Public Citizen Group.
Read more on our Crestor Information Page >>